Business Wire

Dyne.org, RIDDLE&CODE and InfoCert's Consortium Appointed to Take EBSI to the Next Level

21.9.2021 11:05:00 EEST | Business Wire | Press release

Share

The consortium formed by Dyne.org, RIDDLE&CODE and InfoCert, has been selected by the European Commission as one of seven contractors to develop the next version of the European Blockchain Services Infrastructure (EBSI) .

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005128/en/

The award is one more milestone in the consortium's track record of excellence with cryptography and blockchain, after Dyne.org led the flagship H2020 project DECODE, RIDDLE&CODE's blockchain solutions are deployed in banking and utility markets Europe wide and InfoCert being the largest Certification Authority at European level and eIDAS certified QTSP.

The European Commission's vision for EBSI is to leverage distributed ledger technologies to create international and intra-communautaire services for public administrations. The European Blockchain Partnership aims to scale the investment fund to a fully developed platform with up to €2 billion in funding.

The consortium led by the non-profit foundation Dyne.org is developing a multilayered network of blockchains for distributed secure execution of smart contracts, including edge-computing scenarios deployed on low-power embedded devices and chips. The blockchain-agnostic solution offers compatibility with a wide range of products to grant freedom of choice to participating member states and solution developers. Existing integrations include BigchainDB, Ethereum, Hyperledger Fabric, Hyperledger Sawtooth and Bitcoin.

Dyne.org's Zenroom is the core component of the solution. Its portable and secure smart-contract execution environment works standalone (zero dependency) even in a web browser. It can be programmed in a language similar to plain English and guarantees to be functional and portable for two decades to come. Dr. Francesca Bria, president of the Italian National Innovation Fund Cassa Depositi e Prestiti comments: "Zenroom stands for Citizen Crypto. It is a core part of the DECODE tech stack for Smart Cities and it makes it easy to understand the complexity of data transformation while being compatible with any platform, including Legacy Infrastructure. We make Crypto for Citizens and we make it Open Source."

Each member of this consortium gathers together a mature experience developing and deploying industrial standards, as well as facilitating open source community adoption of technologies, including the presence in major blockchain standardisation initiatives such as ISO TC/307, INATBA, W3C and Sovrin.

The combination of blockchain-specific hardware solutions for critical infrastructures, developed by RIDDLE&CODE, will help turn data sources into trusted ones and lay the foundation for EBSI's automated processes and scalability. The combination of InfoCert's leadership and scale when providing services for digital trust, security and identity management complying with standards will allow Europe to adopt mature blockchain solutions to mission-critical environments.

For the initial phase of EBSI's procurement, the consortium proposes a revolutionary solution for a European Digital Product Passport. As a path to success, the consortium plans to work actively to create an open "playing field" in Europe that can easily integrate a diversity of solutions and open this promising industrial field to new players from the public and private sectors.

Quote from the consortium members:

● Andrea D'Intino (EBSI Project leader, Dyne.org): "The consortium's unique combined understanding of cryptography, blockchain and identity technologies as well as its global market positioning, give us the tools and the strength to bring EBSI to the next level. We are truly excited to embrace the policy makers, the businesses and the developers into an inclusive community, to fuel their ideas and products into the European Union's blockchain."

● Thomas Fürstner (Founder & CTO, RIDDLE&CODE): "The blockchain landscape diversifies into layer one and layer two technologies. Layer one is used for attesting values and identities with a small transaction payload and low frequency. Layer two is used for high-volume, low-value, day-to-day transactions. Then, there is the neglected but important layer zero, where blockchain meets products and goods of the physical world. This is exactly where RIDDLE&CODE contributes to EBSI."

● Carmine Auletta (Chief Strategy and Innovation Officer, InfoCert - Tinexta Group): "Being involved in shaping the future EU blockchain infrastructure not only makes us extremely proud, it also could have an important strategic impact on our reference market. An EU blockchain infrastructure could represent the backbone on which EU Trust will be built in the future." He further commented: "InfoCert, as the leading Qualified Trust Service Provider in the EU, aims to further strengthen its thought leadership role in a constantly evolving market. InfoCert has an impressive track record in building innovative solutions and an ambitious R&D program focused on Digital Identity and Digital Trust. It includes the exploitation of emerging technologies, among which blockchain is one of the most promising. Our partners have tremendous technical competencies in distributed ledger technologies, while InfoCert has very distinctive expertise in building Trust Frameworks. Joining forces was natural and proved to be crucial in the success of our consortium."

About RIDDLE&CODE

RIDDLE&CODE is Europe's leading company for blockchain interface solutions. The company develops hardware and software stacks that combine the security of smart cards with blockchain and the Internet of Things (IoT). Together with its tier-one clients and partners, which include Daimler Mobility, BMW, Wien Energie and leading Dutch crypto exchange LiteBit, RIDDLE&CODE brings new business models to the fintech, energy, mobility and materials industries.

More information: www.riddleandcode.com

About Dyne.org

Dyne.org is a non-profit foundation dedicated to free and open source software and community development with 20 years of expertise in developing applications used worldwide. Its motto is "we are free to share code and we code to share freedom" and other projects include independent streaming software for free speech, privacy tools for activists and GNU/Linux distributions.

More information: dyne.org

About InfoCert

InfoCert, Tinexta Group, is the largest European Certification Authority, active in over twenty countries. The company provides services in digitisation, eDelivery, Digital Signature and digital preservation of documents and is an accredited AgID digital identity operator in the area of SPID (Public System for the management of Digital Identity). The company holds a 51% stake in Camerfirma, one of the principal Spanish certification authorities and a 16.7% stake in Authada, a leading-edge German Identity Provider.

More information: infocert.digital

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media contact for RIDDLE&CODE:
Aysenur Yükselal Aji
aysenur@riddleandcode.com

Media contact for Dyne.org
Andrea D'Intino
info@dyne.org

Media contact for InfoCert
comunicazioni@infocert.it

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye